GeneDx Holdings Corp Ordinary Shares - Class A WGS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
-
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
-
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
-
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
-
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
-
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
-
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s
-
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
Trading Information
- Previous Close Price
- $68.74
- Day Range
- $68.51–71.54
- 52-Week Range
- $32.22–170.47
- Bid/Ask
- $70.18 / $70.45
- Shares Outstanding
- 29.82M
- Market Cap
- $2.12B
- Volume/Avg
- 284,916 / 720,472
Key Statistics
- Price/Earnings (Normalized)
- 50.39
- Price/Sales
- 4.42
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,300
- Website
- https://www.genedx.com
Valuation
|
Metric
|
WGS
|
|---|---|
Price/Earnings (Normalized) | 50.39 |
Price/Book Value | 8.39 |
Price/Sales | 4.42 |
Price/Cash Flow | — |
Price/Earnings
WGS
Financial Strength
|
Metric
|
WGS
|
|---|---|
Quick Ratio | 2.90 |
Current Ratio | 3.30 |
Interest Coverage | −34.62 |
Quick Ratio
WGS
Profitability
|
Metric
|
WGS
|
|---|---|
Return on Assets (Normalized) | 2.29% |
Return on Equity (Normalized) | 4.11% |
Return on Invested Capital (Normalized) | 3.33% |
Return on Assets
WGS
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|>!>Pn@$ | LOCK|vx | $254B | |||
| Danaher Corp
DHR
| LOCK|zc&%c%L | LOCK|&#> | $158B | |||
| Agilent Technologies Inc
A
| LOCK|lYz$q&? | LOCK|&^ | $49B | |||
| IQVIA Holdings Inc
IQV
| LOCK|f%ydS$c | LOCK|%LHB | $44B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|$q#KYPb | LOCK|VQh | $44B | |||
| Waters Corp
WAT
| LOCK|Khs@<> | LOCK|r? | $43B | |||
| Illumina Inc
ILMN
| LOCK|$^pl&p> | LOCK|#?w# | $40B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|rX>mpX?> | LOCK|&<f@J | $33B | |||
| Labcorp Holdings Inc
LH
| LOCK|RFflc@DS | LOCK|x<q!n | $26B | |||
| Quest Diagnostics Inc
DGX
| LOCK|mRcj%N | LOCK|N^%g | $26B |
United States